Cargando…

Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin

Dutasteride and tamsulosin are one of the first-line combination therapies for the management of benign prostatic hyperplasia (BPH). Despite being more effective than monotherapies, they produce frequent adverse drug reactions (ADRs). Institutions such as Food and Drug Administration and European Me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villapalos-García, Gonzalo, Zubiaur, Pablo, Navares-Gómez, Marcos, Saiz-Rodríguez, Miriam, Mejía-Abril, Gina, Martín-Vílchez, Samuel, Román, Manuel, Ochoa, Dolores, Abad-Santos, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529037/ https://www.ncbi.nlm.nih.gov/pubmed/34690761 http://dx.doi.org/10.3389/fphar.2021.718281

Ejemplares similares

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism
por: Mejía-Abril, Gina, et al.
Publicado: (2021)

PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Variants in COMT, CYP3A5, CYP2B6, and ABCG2 Alter Quetiapine Pharmacokinetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2023)

Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety
por: Soria-Chacartegui, Paula, et al.
Publicado: (2023)

Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
por: Villapalos-García, Gonzalo, et al.
Publicado: (2023)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

CYP2C8 *3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride
por: Campodónico, Diana María, et al.
Publicado: (2022)

Genotype-Guided Prescription of Azathioprine Reduces the Incidence of Adverse Drug Reactions in TPMT Intermediate Metabolizers to a Similar Incidence as Normal Metabolizers
por: Casajús, Ana, et al.
Publicado: (2022)

Polymorphism of Drug Transporters, Rather Than Metabolizing Enzymes, Conditions the Pharmacokinetics of Rasagiline
por: Zubiaur, Pablo, et al.
Publicado: (2022)

Patients’ Perceptions of Pharmacogenetic Testing and Access to Their Results: State of the Art in Spain and Systematic Review
por: Zubiaur, Pablo, et al.
Publicado: (2022)

Impact of Sex and Genetic Variation in Relevant Pharmacogenes on the Pharmacokinetics and Safety of Valsartan, Olmesartan and Hydrochlorothiazide
por: Soria-Chacartegui, Paula, et al.
Publicado: (2023)

The Effect of Tamsulosin, Dutasteride Monotherapy and Tamsulosin-Dutasteride Combination on Prostate Smooth Muscle Contractility in BPH Model Wistar Strain Rattus Novergicus
por: Daryanto, Besut, et al.
Publicado: (2023)

Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics
por: Koller, Dora, et al.
Publicado: (2020)

Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
por: Miller, J, et al.
Publicado: (2009)

Effects of dutasteride and tamsulosin on penile morphology in a rodent model
por: Da Silva, Marcello H. A., et al.
Publicado: (2023)

Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2020)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple‐dose trial
por: Koller, Dora, et al.
Publicado: (2020)

Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)
por: Zubiaur, Pablo, et al.
Publicado: (2020)

Pharmacogenetics of Donepezil and Memantine in Healthy Subjects
por: Ovejero-Benito, María C., et al.
Publicado: (2022)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
por: Barkin, Jack
Publicado: (2011)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
por: Djavan, Bob, et al.
Publicado: (2011)

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
por: Ochoa, Dolores, et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
por: Ochoa, Dolores, et al.
Publicado: (2020)

A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model
por: Udeh, Emeka I., et al.
Publicado: (2016)

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
por: Geitona, Maria, et al.
Publicado: (2014)

Bioavailability of Oniria(®), a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers
por: Román Martinez, Manuel, et al.
Publicado: (2022)

Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-β-cyclodextrin nanostructures
por: Kim, Min-Soo
Publicado: (2013)

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Urgent Hospital Admissions Caused by Adverse Drug Reactions and Medication Errors—A Population-Based Study in Spain
por: Mejía, Gina, et al.
Publicado: (2020)

Design of a gelatin microparticle-containing self-microemulsifying formulation for enhanced oral bioavailability of dutasteride
por: Baek, In-hwan, et al.
Publicado: (2015)

The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation
por: Chen, Ning, et al.
Publicado: (2017)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

High-Fat Breakfast Increases Bioavailability of Albendazole Compared to Low-Fat Breakfast: Single-Dose Study in Healthy Subjects
por: Ochoa, Dolores, et al.
Publicado: (2021)

Author’s Response to: ‘Letter to the Editor in Response to: “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”’
por: Zubiaur, Pablo, et al.
Publicado: (2019)

The Cytochrome P450 Homepage
por: Nelson, David R
Publicado: (2009)

Cytochrome P450 eicosanoids in hypertension and renal disease
por: Fan, Fan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q9idjldk2r68d25mq3a28qhgsm